FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255264189> ?p ?o ?g. }

• W4255264189 endingPage "274" @default.
• W4255264189 startingPage "274" @default.
• W4255264189 abstract "Central to the malignant behaviour that endows cancer cells withgrowth advantage is their unique metabolism. Cancer cells canprocess nutrient molecules differently from normal cells and useit to overcome stress imposed on them by various therapies. Thismetabolic conversion is controlled by specific genetic mutationsthat are associated with activation of oncogenes and loss of tumoursuppressor proteins. Understanding these processes is importantas it can lead to the discovery of biomarkers that can predict theaggressiveness of the disease and its response to therapy, and evenmore importantly, to the development of novel therapeutics. A classictumour in this respect is clear-cell renal cell carcinoma (RCC). Inthis review, we will begin with a brief summary of normal cellularbioenergetic pathways, which will be followed by a descriptionof the characteristic metabolism of glucose and lipids in clear-cellRCC cells and its clinical implications. Data relating to the potentialeffect of dietary nutrients on RCC will also be reviewed alongwith potential therapies targeted at interrupting specific metabolicpathways in clear-cell RCC.Le métabolisme unique des cellules cancéreuses est au coeur ducomportement malin qui leur confère un avantage sur le plan de lacroissance. Les cellules cancéreuses peuvent traiter les moléculesde nutriment différemment des cellules normales et utilisent cesmolécules pour surmonter le stress imposé par les différents traitements.La conversion métabolique est contrôlée par des mutationsgénétiques précises associées à l’activation d’oncogènes et à laperte de protéines de suppression tumorale. Il est important debien saisir ces processus, car leur élucidation peut mener à ladécouverte de biomarqueurs permettant de prédire l’agressivité dela maladie et la réponse au traitement et, fait encore plus important,elle peut mener à la mise au point de nouveaux médicaments. À cetégard, l’hypernéphrome à cellules claires représente une tumeurclassique. Dans cet article, nous commençons par résumer brièvementles voies bioénergétiques cellulaires normales, puis nouspoursuivons avec une description du métabolisme caractéristiquedu glucose et des lipides dans les cellules de l’hypernéphrome àcellules claires et ses répercussions cliniques. Les données associéesà l’effet potentiel des nutriments sur l’hypernéphrome à cellulesclaires seront aussi passées en revue, ainsi que les thérapiesciblées potentielles visant l’interruption de voies métaboliquesparticulières dans l’hypernéphrome à cellules claires." @default.
• W4255264189 created "2022-05-12" @default.
• W4255264189 creator A5000779166 @default.
• W4255264189 creator A5014636429 @default.
• W4255264189 creator A5027433718 @default.
• W4255264189 creator A5064301549 @default.
• W4255264189 creator A5072029775 @default.
• W4255264189 date "2013-04-05" @default.
• W4255264189 modified "2023-10-01" @default.
• W4255264189 title "Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications" @default.
• W4255264189 doi "https://doi.org/10.5489/cuaj.665" @default.
• W4255264189 hasPublicationYear "2013" @default.
• W4255264189 type Work @default.
• W4255264189 citedByCount "0" @default.
• W4255264189 crossrefType "journal-article" @default.
• W4255264189 hasAuthorship W4255264189A5000779166 @default.
• W4255264189 hasAuthorship W4255264189A5014636429 @default.
• W4255264189 hasAuthorship W4255264189A5027433718 @default.
• W4255264189 hasAuthorship W4255264189A5064301549 @default.
• W4255264189 hasAuthorship W4255264189A5072029775 @default.
• W4255264189 hasBestOaLocation W42552641891 @default.
• W4255264189 hasConcept C121608353 @default.
• W4255264189 hasConcept C126322002 @default.
• W4255264189 hasConcept C143998085 @default.
• W4255264189 hasConcept C1491633281 @default.
• W4255264189 hasConcept C185592680 @default.
• W4255264189 hasConcept C2777472916 @default.
• W4255264189 hasConcept C502942594 @default.
• W4255264189 hasConcept C55493867 @default.
• W4255264189 hasConcept C71924100 @default.
• W4255264189 hasConcept C86803240 @default.
• W4255264189 hasConceptScore W4255264189C121608353 @default.
• W4255264189 hasConceptScore W4255264189C126322002 @default.
• W4255264189 hasConceptScore W4255264189C143998085 @default.
• W4255264189 hasConceptScore W4255264189C1491633281 @default.
• W4255264189 hasConceptScore W4255264189C185592680 @default.
• W4255264189 hasConceptScore W4255264189C2777472916 @default.
• W4255264189 hasConceptScore W4255264189C502942594 @default.
• W4255264189 hasConceptScore W4255264189C55493867 @default.
• W4255264189 hasConceptScore W4255264189C71924100 @default.
• W4255264189 hasConceptScore W4255264189C86803240 @default.
• W4255264189 hasIssue "4" @default.
• W4255264189 hasLocation W42552641891 @default.
• W4255264189 hasOpenAccess W4255264189 @default.
• W4255264189 hasPrimaryLocation W42552641891 @default.
• W4255264189 hasRelatedWork W10819587 @default.
• W4255264189 hasRelatedWork W14537455 @default.
• W4255264189 hasRelatedWork W14648577 @default.
• W4255264189 hasRelatedWork W17296605 @default.
• W4255264189 hasRelatedWork W20638054 @default.
• W4255264189 hasRelatedWork W22553895 @default.
• W4255264189 hasRelatedWork W23212397 @default.
• W4255264189 hasRelatedWork W32378874 @default.
• W4255264189 hasRelatedWork W5191846 @default.
• W4255264189 hasRelatedWork W22711056 @default.
• W4255264189 hasVolume "5" @default.
• W4255264189 isParatext "false" @default.
• W4255264189 isRetracted "false" @default.
• W4255264189 workType "article" @default.